Paller said that dupilumab can effectively treat the immune systems of these children with eczema, reduce their series of allergic problems, and improve their lives; situational photo. (Picture taken from photAC)
[Health Channel/Comprehensive Report]Eczema is a kind of dermatitis that can make the skin red, dry and itchy, seriously affecting the lives of patients and their families. According to statistics, more than 19% of children under the age of 6 suffer from eczema. Regarding eczema in young children, a US study used the first biological drug, rather than an immunosuppressive drug, to treat young children with eczema between the ages of 6 months and 5 years. The study was published in the well-known medical journal “Lancet》（the Lancet）。
according to”Science Daily(Science Daily) reports that a course of dopilumab, a biologic drug targeting the immune pathway of allergy, is the first monoclonal antibody against any skin disorder, including eczema, to be administered in 6-month-old children. A large-scale, randomized, placebo-controlled trial. The study, conducted at 31 sites in Europe and North America, helped more than half of young children reduce eczema symptoms by 75%, resulting in less itching and better sleep.
Please read on…
Debilitating pruritus in children can lead to sleep disturbances, poor neurodevelopment and, on average, a full night of sleep per week, said study author Amy Paller, chair of dermatology at Northwestern University Feinberg School of Medicine. . Paller mentioned that taking the drug will significantly improve the quality of life of infants and young children with the disease. He also said that eczema or atopic dermatitis is not just itchy skin, it is a devastating disease, severe eczema can have a huge impact on the quality of life of children and their parents.
Paller noted that based on the results of the study, the drug is now available for 6-month-old infants and preschoolers. It has an excellent safety profile and doesn’t even require any lab testing before starting the medication. He also said they should not use immunosuppressive drugs, such as oral steroids, when they treat severe eczema and should try to avoid their use in children because they are associated with many side effects. Paller is concerned about the long-term effects of immunosuppressants on the development of the immune system in young children, so this is not the treatment of choice.
The drug dupilumab, developed over the past few years, is the first targeted “biologic drug” to treat eczema and has been found to be effective and safe in studies of adults, adolescents and other school-aged children. In addition to this, the drug has been shown to be effective in the treatment of asthma, allergic gastrointestinal manifestations and other allergic problems, but it has not been approved for these indications in infants and young children.
But Paller was concerned that people under the age of 5 were untested to get the drug, so they conducted a trial: Parents and health care providers gave their children monthly injections of the drug. The results showed that the treatment effect was significant. Other risky, inhibitor-free drugs work just as well.
In the trial, 66% of the children developed eczema within 6 months of life, and more than 80% had developed at least 1 allergic disorder, such as asthma or food allergy. Paller said that by more aggressively treating the immune systems of these young children with severe eczema, a range of allergies could be reduced, which would not only change the eczema, but change their lives. Paller said the findings could allow scientists and doctors to better understand the relationship between eczema and various allergic conditions, and to consider using the drug for other conditions in young children.
☆Do not miss health news, follow by likefan page。
☆For more important medical news, please go toFree Health Network。
No need to draw, no need to grab, now use the APP to watch the news to ensure that you will win the lottery every dayClick me to download APP
Follow me to see how the event works